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Abstract
Long-term opioidsmay benefit patients with chronic pain but have also been linked to harmful outcomes. In the United Kingdom, the
predominant source of opioids is primary care prescription. The objective was to examine changes in the incidence, length, and
opioid potency of long-term prescribing episodes for musculoskeletal conditions in UK primary care (2002-2013). This was an
observational database study (Clinical Practice Research Datalink, 190 practices). Participants ($18 years) were prescribed an
opioid for a musculoskeletal condition (no opioid prescribed in previous 6 months), and issued $2 opioid prescriptions within 90
days (long-term episode). Opioids were divided into short- and long-acting noncontrolled and controlled drugs. Annual incidence of
long-term opioid episodes was determined, and for those still in a long-term episode, the percentage of patients prescribed each
type 1 to 2 years, and.2 years after initiation. Annual denominator population varied from 1.25 to 1.38 m. A total of 76,416 patients
started 1 long-term episode. Annual long-term episode incidence increased (2002-2009) by 38% (42.4-58.3 per 10,000 person-
years), remaining stable to 2011, then decreasing slightly to 55.8/10,000 (2013). Patients prescribed long-acting controlled opioids
within the first 90 days of long-term use increased from 2002 to 2013 (2.3%-9.9%). In those still in a long-term opioid episode (.2
years), long-acting controlled opioid prescribing increased from 3.5% to 22.6%. This study has uniquely shown an increase in
prescribing long-term opioids to 2009, gradually decreasing from 2011 in the United Kingdom. The trend was towards increased
prescribing of controlled long-acting opioids and earlier use. Further research into the risks and benefits of opioids is required.
Keywords: Analgesic, Opioid, Trends, Prescriptions, Musculoskeletal pain, Long-term care
1. Introduction
Over 20% of adults in the United Kingdom present to primary
care with a musculoskeletal (MSK) condition each year.21
Guidance from the World Health Organisation and the UK
National Institute for Health and Care Excellence (NICE)
suggest using opioids as part of a stepped approach to
controlling MSK pain.16,30 This advice advocates incremental
increases from analgesics such as paracetamol to stronger
analgesics such as opioids. Previous studies suggest that
approximately 50% of patients consulting with MSK pain will be
prescribed an analgesic at first consultation,10,27 of which 29%
will be prescribed an opioid within 2 weeks.29
There is evidence that opioid use often continues long-term
(.3 months).3,43 In some patients with chronic pain, opioid use
has been found to be beneficial,12,31 but their use has been
associated with potential harms including dependence, addic-
tion, self-poisoning, and bone fractures.9,37 Increases in preva-
lent long-term opioid use between 1997 and 2005 have been
highlighted in the United States, doubling to approximately 46 per
1000 individuals.3 In the United States, the use of opioids is under
increasing scrutiny, and governmental measures have been
enacted to deal with what is seen as an increasing epidemic of
opioid use and abuse.32 However, the trends in long-term opioid
use seen in the United States may not be reflected in other
westernised countries because of differences in health care
systems and prescribing guidelines. Two studies have shown
substantial increases in UK primary care prescribing of potent
opioids from 2001 to 2010. One using a regional (North
Staffordshire) general practice database (Consultations in Pri-
mary Care Archive, CiPCA) found a doubling of potent opioid use
(from 545 to 1032 per 10,000 registered population),1 whereas
a study using the national Clinical Practice Research Datalink
(CPRD), found an increase in prevalence of potent opioid use
from 1.8 to 9.2 per 1000 registered patients.46 However, none of
these studies examined the changing patterns of new primary
care prescribing of long-term opioids, and it remains unclear
whether the frequency of administering patients long-term
opioids is changing given the guidance available. In particular it
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is not known whether doctors are using more opioids of all types
for longer periods of time, and whether, in those patients
prescribed long-term opioids, there is a trend in the opioid
formulations used towards increasingly potent types. Less
potent, noncontrolled opioids can be bought over-the-counter,
and opioids are prescribed in secondary care settings such as
pain clinics or specialist opioid addiction clinics, but the
predominant source of opioid prescriptions is primary care.7,35
Understanding what is happening with respect to prescribing
long-term opioids in primary care is important because the
potential adverse effects and abuse that have been seen in the
United States.26
The objectives were to examine changes in the incidence and
length of episodes of long-term opioid prescribing for MSK
conditions in primary care from 2002 to 2013, and assess
whether the strength of opioids prescribed to long-term users has
changed over that time.
2. Methods
This was an observational database study performed in the CPRD,
a high-quality anonymised database of routinely recorded in-
formation from general practices trained and assessed in their
recording of information. The data comprise approximately 14
million patients with around 5.4 million of these being currently
active, and registered in 660 primary care practices spread
throughout the United Kingdom.20,40 In England, 98% of the
population are registered with a general practice,18,33 and it is in
primary care that 90%of all National Health Service (NHS) contacts
occur.15 The practices that constitute CPRD offer a representative
sample of the UK population providing a comprehensive database
of primary care prescribing, consultations, and diagnostic coding
that has been validated in previous studies.20,45 For the purposes
of future analysis, practices included were required to have linked
Office for National Statistics, deprivation, and Hospital Episode
Statistics data. Practices with linkage have been shown to be
similar to CPRD practices without linkage on age, deprivation,
body mass index, years of follow-up, and prescription of drugs.13
We also restricted this analysis to the 190 practices who
continuously contributed to CPRD between 2002 and 2013. The
denominator population was taken from currently active patients
aged 18 and over in these 190 practices.
We identified patients aged 18 years plus, starting a long-term
opioid (defined below) at the time of a recorded noninflammatory
potentially painful MSK condition in primary care. Visits to the
primary care physician for MSK conditions were identified using
previously defined Read codes taken fromChapters 1 (History and
symptoms), N (Musculoskeletal), R (Symptoms), and S (Injury).19,21
Read codes are a commonly used method of recording morbidity
in UK primary care. The codes used in this study are available from
the authors. Patients were included if theMSK visit occurred within
a period lasting from 14 days before the initial opioid prescription,
and up to 90 days after it. This was done to link theMSKproblem to
theprescription, because theopioid prescriptionsconsideredwere
long term and a painful MSK problem occurring within that time
framewill be affected by it. Each participantwas required to have at
least 12 months of records in the CPRD database before the initial
opioid prescription and have no record of cancer before the initial
opioid prescription and up to 6 months after the initial opioid
prescription.
Opioidswere defined as analgesics used to relievemoderate to
severe pain from sections 4.7.1 and 4.7.2 of the British National
Formulary.2 The start of a long-term prescription of opioids was
determined as the date of issue of an opioid prescription where
the patient had not received any opioid prescription for at least
a period of 6 months before this date. An episode of long-term
use was defined as at least 3 opioid prescriptions issued within
a 90-day period from the date of the new opioid prescription. An
episode of long-term opioid use endedwhen there was a gap of 6
months or more without an opioid prescription. This definition is
based on a classification of long-term opioid use that has been
used in previous studies.9,43 The end date of a long-term opioid
episode was set at 28 days after the issue of the last prescription
for the opioid in keepingwith local health authority guidance to set
amaximumof a 28-day supply ofmedication per prescription and
for schedule 2 and 3 opioids, no longer than 30 days.8,42 In the
United Kingdom, patients do not have to return to their primary
care physician for every repeat prescription of their opioid, and
can obtain them on a monthly basis from their medical practice
using a doctor-authorised repeat prescription service.
Opioids were grouped according to whether they were
controlled or noncontrolled drugs. The UK classification of
controlled drugs, specifically schedules 2 and 3 of the misuse
of drugs legislation,2,42 specifies which opioid analgesics are
classified as controlled drugs and are subject to specific legal
requirements when these drugs are prescribed. Opioids can be
compared in potency by using their morphine equivalent dose,
which is the amount of morphine that achieves the same
analgesic effect of the opioid in question. Controlled drugs are
made up of themost potent opioid analgesics such oxycodone, in
which 1 mg is equivalent to 1.5 mg of morphine (ie, 50% stronger
than morphine). Noncontrolled opioids include less potent
opioids such as codeine, in which 1 mg is equivalent to 0.15
mg of morphine. These opioids were then further stratified by
determining whether they were a short-acting analgesic (duration
of effect 4-6 hours) or a long-acting one (minimum of 12 hours).
2.1. Statistical analysis
The total number of patients receiving new episodes of long-term
MSK-related opioid prescriptions from 2002 to 2013 was
identified and the total number of such episodes as defined
above was determined for these patients.
2.1.1. Incident prescribing
Annual incidence of episodes of long-term opioid prescribing for
MSK conditions was determined for each year from 2002 to
2013. The numerator was all patients starting a new episode of
long-term opioids in that calendar year. The denominator
population was person-years of all registered patients in a year
not currently prescribed opioids. Annual incidence is reported per
10,000 person-years (with 95% confidence interval) stratified by
age and sex. For the year 2013, the annual incidence is estimated
from the data of the first 9 months because the data for 2014
required to determine new episodes of long-term prescribing for
the fourth quarter of 2013was not available at the time of analysis.
We also determined the percentage of episodes lasting more
than 1 year, and the percentage lasting more than 2 years,
stratified by year of start of episode.
We also determined annual incidence standardised to the age
and sex distribution of the England 2013 population. Stand-
ardised figures were very similar to unstandardised figures;
hence, we report only unstandardised figures in this study.
To determine points of change in trends, we determined the
quarterly incidence of long-term opioid prescribing (per 10,000
person-quarters). The quarters were defined on a seasonal basis
from the first quarter of 2002 (comprising January, February, and
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March) to the third quarter of 2013 (July, August, andSeptember).
Quarterly incidence figures were seasonally adjusted (using
multiplicative model, seasonal decomposition function, SPSS
21). Joinpoint regression was used to identify quarters in which
a statistically significant change (the “joinpoint”) in the underlying
trend in opioid prescribing occurred.11,22,28 The date of these
joinpoints can then be matched to dates of external influences
such as prescribing guidelines. This does not confirm that the
change is linked to these influences but would suggest some
influence on prescribing. If no joinpoints are identified, this would
indicate no significant change in the underlying trend in pre-
scribing between 2001 and 2013. Permutation tests using Monte
Carlo methods were used to determine the minimum number of
joinpoints required to provide an adequate fit to the data. The
analysis started with the minimum number of joinpoints and
testedwhether one ormore joinpoints were statistically significant
(P, 0.05) and should be added to the model (up to 5 joinpoints).
Models were fitted using the joinpoint regression program
(version 4.1.1),28 and the best-fitting model was chosen.
2.1.2. Subgroup prescribing
Wedetermined the percentage of people prescribed each type of
opioid (long or short-acting, controlled, or noncontrolled) at the
initial opioid prescription and within 90 days of the start of the
episode. Likewise, we determined for those still in a long-term
opioid episode the percentage of patients prescribed each type
of opioids 1 to 2 years, and more than 2 years after their episode
start. If a patient was prescribed more than 1 type of opioid, we
used the highest ranking opioid based on the following order
(highest to lowest): controlled long-acting opioid (group 4),
controlled short-acting opioid (group 3), noncontrolled long-
acting opioid (group 2), noncontrolled short-acting opioid
(group 1).
2.1.3. Sensitivity analysis
A sensitivity analysis was performed also including practices
which joined or left CPRD between 2002 and 2013 to determine
whether changes in the practice profiles influenced the findings.
Analysis was performed using STATA MP 13.1 and SPSS 21.
3. Results
The denominator population varied from 1,253,300 in 2002 to
1,379,217 in 2011, but the age and sex structure remained
largely consistent (Appendix 1, available online as Supplemen-
tal Digital Content at http://links.lww.com/PAIN/A255). Be-
tween 2002 and 2013, a total of 76,416 patients with
a potentially painful MSK consultation were identified as
starting at least 1 episode of a long-term opioid. In total,
84,184 episodes were identified, with 57,171 (67.9%) being
completed episodes by the end of 2013. Uncompleted
episodes were either due to end of patient’s registration or
end of study follow-up. The median episode length was 227
(interquartile range 98, 673) days. This will be an underestimate
as it includes the 32% of episodes that were not completed.
The annual incidence of long-term opioids for patients with
MSK conditions increased by 38% from 2002 (incidence 42.4
per 10,000 person-years) to 2009 (58.3/10,000), and then
remained approximately stable until decreasing slightly in 2012
and 2013 to levels that were just below those in 2009 (55.8/
10,000) (Table 1). Joinpoint regression analysis indicated the
levelling out of the increasing trend started in the fourth quarter
of 2008, and the slight decrease in incidence started from the
third quarter of 2011 (Fig. 1).
Females and those in the older age group ($65 years) were
more likely to start new episodes of long-term opioids, but trends
over time were similar across sex and age groups (Table 1). Of
note, 42.3% of those starting a new long-term opioid prescription
in 2002 were in that episode for more than a year, decreasing to
38.8% by 2012, and 28.6% for more than 2 years, which
remained consistent over time (Table 2).
Table 1
Annual incidence of the start of long-term opioid prescribing episodes.
Year Incidence per 10,000 person-years (95% confidence interval)
Overall Male 18-44 Male 45-64 Male 651 Female 18-44 Female 45-64 Female 651
2002 42.4 (41.2-43.6) 16.4 (15.0-18.0) 40.2 (37.5-43.1) 70.3 (65.6-75.2) 22.5 (20.8-24.3) 51.6 (48.5-54.9) 96.9 (92.1-101.9)
2003 45.5 (44.4-46.7) 16.8 (15.4-18.4) 45.0 (42.2-48.0) 73.1 (68.4-78.1) 25.2 (23.4-27.1) 53.7 (50.5-56.9) 105.1 (100.1-110.2)
2004 48.7 (47.5-50.0) 18.6 (17.1-20.3) 45.3 (42.5-48.3) 79.4 (74.4-84.5) 25.6 (23.8-27.5) 59.0 (55.7-62.4) 114.2 (109.0-119.6)
2005 49.9 (48.7-51.2) 19.1 (17.6-20.7) 47.9 (45.1-50.9) 84.6 (79.6-90.0) 25.3 (23.5-27.2) 60.8 (57.5-64.2) 113.7 (108.6-119.0)
2006 53.2 (51.9-54.4) 20.6 (19.0-22.3) 50.5 (47.6-53.6) 86.9 (81.8-92.2) 28.0 (26.1-30.0) 62.7 (59.4-66.1) 124.6 (119.2-130.1)
2007 56.5 (55.3-57.8) 21.8 (20.1-23.5) 53.6 (50.7-56.8) 91.1 (86.0-96.5) 29.1 (27.2-31.1) 67.2 (63.8-70.7) 133.4 (127.9-139.1)
2008 56.6 (55.4-57.9) 21.4 (19.8-23.1) 54.5 (51.5-57.6) 88.5 (83.4-93.7) 31.5 (29.6-33.6) 68.6 (65.2-72.1) 128.1 (122.7-133.6)
2009 58.3 (57.0-59.6) 23.9 (22.2-25.7) 57.8 (54.7-60.9) 91.1 (86.1-96.3) 32.7 (30.7-34.8) 68.9 (65.6-72.4) 125.9 (120.6-131.4)
2010 57.7 (56.5-59.0) 24.7 (22.9-26.5) 56.1 (53.1-59.2) 88.8 (83.9-94.0) 32.1 (30.1-34.2) 68.7 (65.3-72.1) 124.0 (118.8-129.3)
2011 59.7 (58.4-61.0) 24.5 (22.7-26.3) 56.7 (53.7-59.9) 90.2 (85.3-95.2) 33.7 (31.7-35.9) 73.5 (70.0-77.0) 125.4 (120.2-130.7)
2012 56.2 (54.9-57.4) 25.0 (23.2-26.9) 54.6 (51.6-57.7) 80.7 (76.2-85.5) 34.5 (32.3-36.7) 67.6 (64.3-71.0) 108.7 (104.0-113.7)
2013 55.8 (54.5-57.1) 24.2 (22.4-26.2) 51.3 (48.4-54.4) 89.0 (84.3-94.0) 31.2 (29.1-33.4) 63.1 (59.8-66.5) 108.7 (103.9-113.6)
Figure 1. Quarterly incident prescribing of long-term musculoskeletal-related
opioids. The lines show the 5 significant (P value, 0.05) joinpoints determined
in the best-fitting model.
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3.1. Subgroup prescribing
In 2002, 96.9% of all first prescribed opioids at the start of
a long-term opioid episode were short-acting less potent
noncontrolled opioids. This decreased slightly to 95.7% by
2013 with the percentage of prescribed long-acting more
potent controlled opioids at their initial prescription increasing
from 0.7% to 2.8% (Table 3). Between 2002 and 2013, the
percentage of people who received a controlled long-term
opioid within the first 90 days of their long-term episode
increased from 2.3% to 9.9%. By 2013, 14.7% of people who
had been in an episode between 1 and 2 years were receiving
long-acting more potent controlled opioids, compared with
only 4.0% in 2003; 22.6% of patients in a long-term episode for
more than 2 years were being prescribed long-acting more
potent controlled opioids in 2013, compared with 3.5% in
2004. Females aged 65 and above were prescribed more long-
acting potent controlled opioids within 90 days of initial start of
a new episode (Fig. 2), but there was little variation by age if
episodes lasted more than 1 year (Fig. 2).
3.2. Sensitivity analysis
Including practices that joined or left CPRD during the study
period (n5 360) in the analysis gave similar trends to the analysis
restricted to those practices continuously contributing to CPRD.
4. Discussion
To our knowledge, this is the first study outside the United States
to demonstrate an increase specifically in prescribing long-term
opioids from 2002 to 2009. However, uniquely, we also observed
a smaller gradual decrease between 2011 and 2013 to levels
similar to those in 2009. Over the 11 years of the study, there was
increased prescribing of the more potent controlled and long-
acting, long-term opioids. Additionally, for the first time, we have
found that there was also an increase in use of more potent
controlled and longer-acting opioids early on in a patient’s long-
term episode, and over a fifth of patients who had been on opioids
Table 2
Length of the episode by year of start of the new long-term
opioid prescription episode.
Episode
start year
No. of new long-
term episodes
n (%) in episode
more than 1 y
n (%) in episode
more than 2 y
2002 5330 2253 (42.3) 1525 (28.6)
2003 5788 2382 (41.2) 1567 (27.1)
2004 6256 2548 (40.7) 1716 (27.4)
2005 6495 2765 (42.6) 1886 (29.0)
2006 6999 2904 (41.5) 2017 (28.8)
2007 7556 3112 (41.2) 2176 (28.8)
2008 7659 3171 (41.4) 2199 (28.7)
2009 7958 3223 (40.5) 2190 (27.5)
2010 7977 3206 (40.2) 2192 (27.5)
2011 8274 3439 (41.6) 2461 (29.7)
2012 7579 2940 (38.8) —
Table 3
Subgroup of opioid prescribed by year and length of time in the episode (%).
Year* Initial prescription Prescriptions within first 90 d
Short-acting
noncontrolled
Long-acting
noncontrolled
Short-acting
controlled
Long-acting
controlled
Short-acting
noncontrolled
Long-acting
noncontrolled
Short-acting
controlled
Long-acting
controlled
2002 96.9 2.1 0.4 0.7 90.7 6.0 1.1 2.3
2003 97.1 1.9 0.3 0.6 90.4 5.7 1.2 2.7
2004 96.8 2.0 0.4 0.8 89.5 6.4 1.1 3.0
2005 96.0 2.4 0.6 1.0 87.8 6.7 1.4 4.0
2006 95.7 2.0 0.5 1.9 87.0 5.3 1.7 6.0
2007 95.2 1.9 0.6 2.4 84.9 5.4 1.6 8.1
2008 94.7 1.8 0.6 2.9 84.6 5.2 1.5 8.6
2009 95.1 1.5 0.4 3.0 85.1 4.6 1.2 9.1
2010 95.1 1.5 0.5 3.0 84.7 4.3 1.2 9.8
2011 95.3 1.4 0.5 2.8 86.2 3.7 1.4 8.7
2012 95.5 1.2 0.5 2.8 87.1 3.1 1.1 8.7
2013 95.7 1.0 0.5 2.8 86.1 2.9 1.1 9.9
Year† Between 1-2 y after start of long-term opioids After 2-y on long-term opioid
Short-acting
noncontrolled
Long-acting
noncontrolled
Short-acting
controlled
Long-acting
controlled
Short-acting
noncontrolled
Long-acting
noncontrolled
Short-acting
controlled
Long-acting
controlled
2002 — — — — — — — —
2003 88.5 6.4 1.1 4.0 — — — —
2004 87.7 6.0 1.3 4.9 88.3 5.9 2.3 3.5
2005 85.5 6.5 1.3 6.7 82.6 8.4 1.7 7.3
2006 82.6 8.1 1.5 7.8 77.2 9.5 1.4 11.9
2007 82.7 6.3 1.4 9.6 74.8 8.2 2.3 14.8
2008 79.2 5.8 1.7 13.3 72.4 7.3 2.5 17.8
2009 77.0 6.3 1.7 15.0 68.8 8.5 1.8 20.9
2010 77.8 5.6 1.5 15.2 68.4 7.7 1.7 22.2
2011 78.9 4.6 1.2 15.3 68.1 6.9 1.8 23.1
2012 78.2 5.3 1.4 15.1 68.0 6.3 1.8 23.9
2013 78.9 5.3 1.1 14.7 69.6 6.2 1.6 22.6
If a patient was prescribed more than 1 type of opioid, we used the highest ranking opioid based on the following order (highest to lowest): controlled long-acting opioid, controlled short-acting opioid, noncontrolled long-acting
opioid, and noncontrolled short-acting opioid.
* Year on which long-term opioid was started.
† Calendar year.
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for more than 2 years were being prescribed more potent
controlled long-acting opioids by 2013.
The increase in incidence of long-term opioids between 2000
and 2009 matches the increasing trend in the prevalence of
opioid use among non-cancer pain patients with chronic pain in
the United States between 1997 and 2006,3,34 and in more
potent controlled opioids in the United Kingdom,46 although
these studies were not restricted to patients with potentially
painful MSK conditions. Chevalier et al. showed that from 2006
to 2011, 1 in 5 UK opioid users were prescribed opioids
chronically (.183 days of continuous use), and that over the
period of their chronic use, the amount they used decreased,
but they did not examine in detail trends over time in prescribing
and looked at the whole population rather than specifically
patients with painful MSK conditions as in this study.5 The
increased use of long-term opioids may reflect beneficial
effects in terms of helping patients with their long-term painful
condition, for there is some evidence that they can help in some
patients.12,31 Indeed, guidelines suggest using opioids if
alternative prescribing strategies have failed, which might
prompt doctors to use opioids in patients in whom pain has
been difficult to control.16,30 However, the increasing incidence
of prescribing long-term opioids started slowing down shortly
after the introduction of the NICE guidance on management of
osteoarthritis (February 2008) when the recommendation was
to use opioids only after weaker analgesia had been tried.
Shortly after the US Government’s Office of National Drug
Control Policy guidance (April 2011),32 the incidence of long-
term opioid prescribing in the United Kingdom started to
gradually decline to the same levels as those in 2009. The
increased use of opioids over the previous decade in the United
States and an apparent increase in abuse of long-acting
opioids had led to this US initiative.26 Although any direct
connection of the US guidance to prescribing in the United
Kingdom cannot be determined here, it is possible that its
message and the well-documented increase in opioid pre-
scribing in the United States26 may have had some “spill over”
effect through the medical media into the United Kingdom.
Since 2013, initiatives in the United Kingdom have recom-
mended action to underpin regulations designed to improve
monitoring and use of controlled drugs such as strong opioids.4,6
However, it would appear from this study that nationally from
2011, primary care physicians had already acted to reduce their
use of new opioids, but in cases in which opioids were being
prescribed, the shift towards using the more potent controlled
and long-acting opioids continued. The increased use of
controlled opioids is in keeping with the findings of other
European studies.17,36,46 Although less potent noncontrolled
opioid prescriptions still make up the majority of initial prescrip-
tions for opioids, it was evident that primary care physicians did
change to the more potent controlled opioids even within the first
90 days of a long-term episode. Those on more potent controlled
opioids, either short-acting or long-acting, are of the greatest
concern in relation to prescription opioid drug abuse. Our results
show that a quarter of patients starting long-term opioids will still
be on themmore than 2 years later, and over a fifth of these will be
on long-acting controlled prescriptions, raising concerns about
the potential for abuse and addiction among this group of users.
Guidelines that are now being incorporated into normal prac-
tice4,6 need to ensure clear messages around appropriate use of
opioids, including the correct dosage and indications for
continued use. Regular review would also ensure that opioid
use is only continued when necessary, reducing the potential for
addiction and side effects.
Figure 2. Percentage of patients receiving long-acting controlled opioid prescription by age, sex, and length of time in episode: (A) initial opioid prescription, (B)
prescribed within 90 days, (C) using opioids for between 1 - 2 years, and (D) using opioids for more than 2 years.
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Those in the older age groups had higher rates of long-term
opioid prescribing and of stronger opioids early on in these
episodes. A higher rate of opioid use in older age groups has also
been found in other studies.14,36,46 This group poses a dilemma
for clinicians, as they are at increased risk of side effects,9,37 and
hence the clinically rational approach would be to use less potent
opioids in these patients. However, they are more likely to be
affected by severely painful MSK conditions,21 and aremore likely
to have adverse effects from alternatives, such as nonsteroidal
anti-inflammatory drugs.23 Females had higher rates of new
prescriptions for long-term opioids compared with males. This is
also consistent with other work,3,34,36 and may reflect the higher
prevalence of painful MSK conditions among females.21
This study used a novel method to identify opioid subgroups
using the classification according to the UK Misuse of Drugs Act
schedule of controlled drugs.41 We did not use morphine
equivalent dose or daily defined dose44 as has been used in
previous studies,17,46 but this classification allows direct com-
parison of less potent (noncontrolled) opioids with the more
potent controlled opioids of schedules 2 and 3 that are of major
concern for prescribers and regulating bodies in terms of the
potential for abuse of long-acting opioid medications.4,6 Opioids
cannot be directly marketed to patients in the United Kingdom,
unlike in the United States where marketing may have influenced
increases in the use of long-term opioids.39 Management of
established abuse and addiction is included in UK guidelines,
which clearly define the prescribing of pharmacological inter-
ventions to treat addiction.7 These strict criteria, which often
require the use of specialist services, predetermine opioid use
and will have some bearing on the opioid prescribing we have
described. However, within the opioids examined here, metha-
done (an opioid primarily used in the United Kingdom as
a substitute in opioid withdrawal) was not included as one of
the opioids we examined for this reason.
An advantage of our study was that all prescribing is recorded
in CPRD at the point of medication issue in the visit to the primary
care physicians, and all repeat prescriptions of these drugs are
recorded automatically so missing any opioid data is unlikely. We
examined only patients who had potentially painful MSK
conditions, and our findings may not be generalisable to opioids
prescribed for other conditions, such as pain in cancer, or
neuropathic pain. However, among patients reporting chronic
pain, there are comparatively few with neuropathic pain.38 Some
errors in underrecording or coding of MSK conditions might have
occurred leading to an underestimation of opioid use. However,
historically, GPs in practices contributing to CPRD have been
required to enter morbidity codes at a minimum for a new
diagnosis or when treatment has changed; therefore, most new
prescribing of opioids in consulters should have been identified.24
It is possible that not all the opioids within an episode were
prescribed for the initial MSK condition.
This analysis relates to information on all patients prescribed
opioids, and not just those with health insurance as in studies
from the United States, thereby making the results more
generalisable to westernised populations outside the United
States. Accordingly, the increasing use of long-acting stronger
opioids in patients on long-term opioids indicates the continu-
ing need to promote vigilance regarding the ongoing use of
opioids among patients with MSK conditions in Europe and
further afield. Although the overall prescribing of opioids for
MSK conditions has reduced in the most recent years, in the
light of recent evidence suggesting lack of effectiveness of
paracetamol for knee and back pain,25 doctors may in the
future change their prescribing habits again in an attempt to
help resolve their patients’ MSK pain, possibly driving a further
increase in prescribing opioids. Monitoring with regular review
and assessment of analgesic needs in the patients receiving
opiates might reduce the potential for their abuse and helping
to determine their effectiveness in controlling chronic pain.
Further research to determine whether such changes are being
implemented will be required in the future.
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